Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP003396)
SBP Name
I-body AD-214
Synonyms
AD 214
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Expression System Escherichia coli
Highest Status Phase I
Protein Scaffold Information of This SBP
Scaffold ID PS040
Scaffold Info
[1]
Scaffold Name I-body
Scaffold Class Non-Antibody
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Fc receptor
BTS Info
Binder Fibrosis [ICD-11: CA25.Z] N.A. AdAlta; La Trobe University [1]
C-X-C chemokine receptor type 4
BTS Info
Antagonist Fibrosis [ICD-11: CA25.Z]; Interstitial lung diseases [ICD-11: CB0Z]; Age related macular degeneration [ICD-11: 9B75.0] N.A. AdAlta; La Trobe University [1]
Clinical Trial Information of This SBP
NCT04415671 Click to show the Detail
Indication Interstitial Lung Disease
Phase Phase I
Title Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers
Status Recruiting
Sponsor AdAlta Limited
NCT04494243 Click to show the Detail
Indication Gastroesophageal Reflux Disease
Phase Phase I
Title A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
Status Completed
Sponsor Addpharma Inc
NCT04622358 Click to show the Detail
Indication Gastroesophageal Reflux Disease
Phase Phase I
Title A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole
Status Completed
Sponsor Addpharma Inc
NCT05062876 Click to show the Detail
Indication Gastroesophageal Reflux Disease
Phase Phase I
Title A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
Status Completed
Sponsor Addpharma Inc.
NCT05914909 Click to show the Detail
Indication Interstitial Lung Disease|Chronic Kidney Diseases
Phase Phase I
Title Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease
Status Completed
Sponsor AdAlta Limited
References
1 AdAlta. Product Development Pipeline. 2021.